

August 1, 2017



# Matinas BioPharma to Host Quarterly Update Conference Call

- Conference call with live audio webcast on Tuesday, August 8<sup>th</sup> at 8:30 am ET –
- Management to outline and confirm clinical and regulatory strategy of flagship product candidate MAT2203 toward Phase 3 in prevention of invasive fungal infections –

BEDMINSTER, N.J., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that it will report its operational and financial results for the second quarter ended June 30, 2017 in a press release that will be issued pre-market on Tuesday, August 8, 2017. The Company also announced that it will host a quarterly and business update conference call with a live audio webcast that same day at 8:30 AM ET.

During the conference call, members of the Matinas management team will review the Company's operational progress, expected near-term milestones and quarterly financial overview. Following recent Phase 2 data announcements for its lead product candidate, MAT2203, management will also outline and confirm the clinical and regulatory strategy for this program, including its plans to engage with the U.S. Food and Drug Administration ("FDA") to review the compelling overall human safety, tolerability and efficacy data package generated with MAT2203 to date with the goal of entering Phase 3 for the prevention of invasive fungal infections as quickly as possible. Besides the important results from three human studies, the growing body of positive data for MAT2203 includes strong preclinical efficacy data in a range of life-threatening invasive fungal infections.

The conference call and live [webcast](#) will be accompanied by a slide presentation. To participate in the call, please dial (877) 407-5976 (domestic) or (412) 902-0031 (international). The live webcast and accompanying slides will be available on the [Events](#) page of the [Investors](#) section of the Company's website ([www.matinasbiopharma.com](http://www.matinasbiopharma.com)), and will be archived for 60 days.

## About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. The Company's proprietary, disruptive platform technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable.

The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology.

For more information, please visit [www.matinasbiopharma.com](http://www.matinasbiopharma.com) and connect with the Company on [Twitter](#), [LinkedIn](#), [Facebook](#), and [Google+](#).

**Forward Looking Statements:** *This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's strategic focus and the future development of its product candidates, including MAT2203 and MAT2501, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the Company's ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to maintain and derive benefit from the Qualified Infectious Disease Product (QIDP), Orphan and/or Fast Track designations for MAT2203 and MAT2501, which does not change the standards for regulatory approval or guarantee regulatory approval on an expedited basis, or at all; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.*

Investor Contact  
Jenene Thomas  
Jenene Thomas Communications, LLC  
Phone: +1 (908) 938-1475  
Email: [jenene@jenenethomascommunications.com](mailto:jenene@jenenethomascommunications.com)



Source: Matinas BioPharma Holdings, Inc.